pt en es

Reagentes e instrumentos para imunologia, biologia celular e biologia molecular.

Ciprofloxacin [85721-33-1]

Imprimir

Referência HY-B0356-5g

Tamanho : 5g

Contactar o distribuidor local :

Telefone : +1 850 650 7790

Marca : MedChemExpress

Solicitar mais informações

Contactar o distribuidor local :

Telefone : +1 850 650 7790

Description

Ciprofloxacin (Bay-09867) is a potent, orally active topoisomerase IV inhibitor. Ciprofloxacin induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin has anti-proliferative activity and induces apoptosis. Ciprofloxacin is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity^[1]^[2]^[3]^[4].

IC₅₀ & Target

Quinolone

Cellular Effect

Cell Line	Type	Value	Description	References
A-431	IC₅₀	>128 μM Compound: CFX	Anticancer activity against human A-431 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human A-431 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31881454]
A-431	IC₅₀	135 μM Compound: 1	Inhibition of human A431 cell proliferation by MTT assay Inhibition of human A431 cell proliferation by MTT assay	[PMID: 19595598]
A-431	IC₅₀	137 μM Compound: Ciprofloxacin	Cytotoxicity against human A431 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human A431 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
A549	IC₅₀	>100 μM Compound: Ciprofloxacin	Antiproliferative activity against human A549 cells after 24 hrs by BrdU incorporation assay Antiproliferative activity against human A549 cells after 24 hrs by BrdU incorporation assay	[PMID: 27555286]
A549	IC₅₀	>302 nM Compound: Ciprofloxacin	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 30660827]
A549	IC₅₀	0.33 mM Compound: CFX	Antitumor activity against human A549 cells assessed as reduction in cell viability incubated for 4 hrs by MTT assay Antitumor activity against human A549 cells assessed as reduction in cell viability incubated for 4 hrs by MTT assay	[PMID: 31881454]
A549	IC₅₀	280 μM Compound: 1	Antitumor activity against human A549 cells after 5 days by MTT assay Antitumor activity against human A549 cells after 5 days by MTT assay	[PMID: 19595598]
B-cell	IC₅₀	123 μM Compound: ciprofloxacin	Antiproliferative activity against Theileria parva-induced proliferation of bovine B lymphocyte assessed as inhibition of [3H]thymidine uptake after 48 hrs Antiproliferative activity against Theileria parva-induced proliferation of bovine B lymphocyte assessed as inhibition of [3H]thymidine uptake after 48 hrs	[PMID: 19075064]
C8166	EC₅₀	100 μM Compound: CPX, ciprofloxacin	In vitro antiviral activity against HIV-1 IIIB in C8166 (human CD4) cells. In vitro antiviral activity against HIV-1 IIIB in C8166 (human CD4) cells.	[PMID: 11020296]
CAPAN-1	IC₅₀	>100 μM Compound: Ciprofloxacin	Cytotoxicity against human Capan1 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human Capan1 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
CHO	CC₅₀	512 μM Compound: CPFX	Cytotoxicity against CHO cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against CHO cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31525660]
CHO	IC₅₀	>150 μM Compound: CFX	Cytotoxicity against Chinese hamster CHO cells assessed as reduction in cell viability by MTT assay Cytotoxicity against Chinese hamster CHO cells assessed as reduction in cell viability by MTT assay	[PMID: 31881454]
CHO	IC₅₀	>150 μM Compound: Ciprofloxacin	Cytotoxicity against CHO cells assessed as reduction in cell viability Cytotoxicity against CHO cells assessed as reduction in cell viability	[PMID: 30660827]
CT26	IC₅₀	0.33 mM Compound: CFX	Antitumor activity against mouse CT26 cells assessed as reduction in cell viability incubated for 4 hrs by MTT assay Antitumor activity against mouse CT26 cells assessed as reduction in cell viability incubated for 4 hrs by MTT assay	[PMID: 31881454]
EJ	IC₅₀	>128 μM Compound: CFX	Anticancer activity against human EJ cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human EJ cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31881454]
EJ	IC₅₀	137 μM Compound: Ciprofloxacin	Cytotoxicity against human EJ cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human EJ cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
EJ	IC₅₀	202 μM Compound: 1	Inhibition of human EJ cell proliferation by MTT assay Inhibition of human EJ cell proliferation by MTT assay	[PMID: 19595598]
HaCaT	IC₅₀	222.1 μM Compound: CP	Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31678743]
HBL-100	IC₅₀	10.28 μM Compound: C; Cip	Cytotoxicity against human HBL-100 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HBL-100 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34319100]
HEK-293T	CC₅₀	>60 μg/mL Compound: Ciprofloxacin	Cytotoxicity against HEK293T cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against HEK293T cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 27720324]
HeLa	EC₅₀	0.03 μM Compound: Ciprofloxacin	Inhibitory activity against HeLa cell Topoisomerase II Inhibitory activity against HeLa cell Topoisomerase II	10.1016/0960-894X(95)00160-U
HeLa	IC₅₀	>100 μM Compound: Ciprofloxacin	Cytotoxicity against human HeLa cells after 24 hrs by LDH release assay Cytotoxicity against human HeLa cells after 24 hrs by LDH release assay	[PMID: 27018907]
HeLa	IC₅₀	120 μg/mL Compound: Ciprofloxacin	Inhibition of metabolic activity in HeLa cells assessed as MTT reduction after 48 hrs Inhibition of metabolic activity in HeLa cells assessed as MTT reduction after 48 hrs	[PMID: 17088489]
HeLa	IC₅₀	270 μM Compound: 1	Inhibition of human HeLa cell proliferation Inhibition of human HeLa cell proliferation	[PMID: 19595598]
HeLa	IC₅₀	290 μg/mL Compound: Ciprofloxacin	Antiproliferative effect against HeLa cells after 48 hrs Antiproliferative effect against HeLa cells after 48 hrs	[PMID: 17088489]
HeLa	IC₅₀	800 μM Compound: 1	Inhibition of human HeLa cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA Inhibition of human HeLa cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA	[PMID: 19595598]
Hep 3B2	IC₅₀	>100 μM Compound: Ciprofloxacin	Cytotoxicity against human Hep3B cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human Hep3B cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
HEp-2	CC₅₀	>100 μM Compound: CIP	Cytotoxicity against human Hep2 cell line after 72 hrs Cytotoxicity against human Hep2 cell line after 72 hrs	[PMID: 17228862]
HEp-2	CC₅₀	>100 μM Compound: CIP	Cytotoxicity against human Hep2 cells after 72 hrs by alamar blue assay Cytotoxicity against human Hep2 cells after 72 hrs by alamar blue assay	[PMID: 21425851]
HEp-2	CC₅₀	>100 μM Compound: CIP	Cytotoxicity against human Hep2 cell line after 72 hrs Cytotoxicity against human Hep2 cell line after 72 hrs	[PMID: 21443219]
HEp-2	CC₅₀	>100 μM Compound: Ciprofloxacin	Cytotoxicity against Hep2 cell line Cytotoxicity against Hep2 cell line	[PMID: 16337789]
HEp-2	CC₅₀	>100 μM Compound: Ciprofloxacin	Cytotoxicity against human Hep2 laryngeal carcinoma cell line Cytotoxicity against human Hep2 laryngeal carcinoma cell line	[PMID: 16337791]
HepG2	CC₅₀	>100 μM Compound: CIP	Cytotoxicity against human HepG2 cells after 72 hrs Cytotoxicity against human HepG2 cells after 72 hrs	[PMID: 17228862]
HepG2	CC₅₀	138.6 μg/mL Compound: CPX	Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by ATP bioluminescence assay Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by ATP bioluminescence assay	[PMID: 30067360]
HepG2	IC₅₀	>0.5 mM Compound: CPX, B-H	Cytotoxicity against human HepG2 cells measured after overnight incubation by MTT assay Cytotoxicity against human HepG2 cells measured after overnight incubation by MTT assay	[PMID: 21855181]
HepG2	IC₅₀	>128 μg/mL Compound: CIP	Cytotoxicity against human HepG2 cells after 24 hrs by cell titre-glo assay Cytotoxicity against human HepG2 cells after 24 hrs by cell titre-glo assay	[PMID: 27499455]
HepG2	IC₅₀	>128 μg/mL Compound: CIP	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability for 24 hrs by Celltiter-Glo assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability for 24 hrs by Celltiter-Glo assay	[PMID: 35231579]
HepG2	IC₅₀	>170 μg/mL Compound: Ciprofloxacin	Cytotoxicity against human HepG2 cells incubated for 40 hrs by celltiter-glo luminescent cell viability assay Cytotoxicity against human HepG2 cells incubated for 40 hrs by celltiter-glo luminescent cell viability assay	[PMID: 38157595]
HepG2	IC₅₀	27 μM Compound: Ciprofloxacin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 7 days by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 7 days by MTT assay	[PMID: 28237557]
HepG2	IC₅₀	37.47 μg/mL Compound: Ciprofloxacin (CPFX)	Cytotoxicity was determined for the compound in HepG2 cell line Cytotoxicity was determined for the compound in HepG2 cell line	[PMID: 14980680]
HL-60	IC₅₀	>100 μM Compound: Ciprofloxacin	Cytotoxicity against human HL60 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
HL-60	IC₅₀	>150 μM Compound: CFX	Cytotoxicity against human HL-60 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HL-60 cells assessed as reduction in cell viability by MTT assay	[PMID: 31881454]
HL-60	IC₅₀	>150 μM Compound: Ciprofloxacin	Cytotoxicity against human HL60 cells assessed as reduction in cell viability Cytotoxicity against human HL60 cells assessed as reduction in cell viability	[PMID: 30660827]
HL-60	IC₅₀	>302 nM Compound: Ciprofloxacin	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 30660827]
HL-60	IC₅₀	>=100 μM Compound: Ciprofloxacin	Antiproliferative activity against human HL60 cells by MTT assay Antiproliferative activity against human HL60 cells by MTT assay	[PMID: 30660827]
K562	IC₅₀	>150 μM Compound: 1	Inhibition of human K562 cell proliferation by sulphorodhamine B assay Inhibition of human K562 cell proliferation by sulphorodhamine B assay	[PMID: 19595598]
KB	IC₅₀	>128 μM Compound: CFX	Anticancer activity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31881454]
KB	IC₅₀	160 μM Compound: 1	Inhibition of human KB cell proliferation by MTT assay Inhibition of human KB cell proliferation by MTT assay	[PMID: 19595598]
L02	IC₅₀	>64 μg/mL Compound: Cip	Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 38096652]
L02	IC₅₀	12.23 μM Compound: Ciprofloxacin	Cytotoxicity against human L02 cells after 72 hrs by CCK-8 assay Cytotoxicity against human L02 cells after 72 hrs by CCK-8 assay	[PMID: 35398730]
L02	IC₅₀	4.05 μg/mL Compound: Ciprofloxacin	Cytotoxicity against human L02 cells after 72 hrs by CCK-8 assay Cytotoxicity against human L02 cells after 72 hrs by CCK-8 assay	[PMID: 35398730]
L1210	IC₅₀	>100 μM Compound: Ciprofloxacin	Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
L1210	IC₅₀	>150 μM Compound: CFX	Antiproliferative activity against mouse L1210 cells assessed as reduction in cell viability by MTT assay Antiproliferative activity against mouse L1210 cells assessed as reduction in cell viability by MTT assay	[PMID: 31881454]
L1210	IC₅₀	>150 μM Compound: CFX	Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability by MTT assay	[PMID: 31881454]
L1210	IC₅₀	>150 μM Compound: Ciprofloxacin	Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability	[PMID: 30660827]
L1210	IC₅₀	>=100 μM Compound: Ciprofloxacin	Antiproliferative activity against mouse L1210 cells by MTT assay Antiproliferative activity against mouse L1210 cells by MTT assay	[PMID: 30660827]
LoVo	IC₅₀	89 μM Compound: 1	Antitumor activity against human LoVo cells after 5 days by MTT assay Antitumor activity against human LoVo cells after 5 days by MTT assay	[PMID: 19595598]
MC3T3-E1	IC₅₀	120 μM Compound: 1	Inhibition of mouse MC3T3-E1 cell proliferation after 48 to 72 hrs Inhibition of mouse MC3T3-E1 cell proliferation after 48 to 72 hrs	[PMID: 19595598]
MCF-10A	IC₅₀	>300 μM Compound: Ciprofloxacin	Cytotoxicity against human MCF10A cells after 48 hrs by WST1 assay Cytotoxicity against human MCF10A cells after 48 hrs by WST1 assay	[PMID: 24513049]
MCF7	CC₅₀	60 μg/mL Compound: Ciprofloxacin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 27720324]
MCF7	IC₅₀	>100 μM Compound: Ciprofloxacin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
MCF7	IC₅₀	>128 μM Compound: CFX	Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31881454]
MCF7	IC₅₀	199 μM Compound: 1	Inhibition of human MCF7 cell proliferation by MTT assay Inhibition of human MCF7 cell proliferation by MTT assay	[PMID: 19595598]
MCF7	IC₅₀	476 μM Compound: 1	Antitumor activity against human MCF7 cells after 5 days by MTT assay Antitumor activity against human MCF7 cells after 5 days by MTT assay	[PMID: 19595598]
MCF7	IC₅₀	76 μM Compound: 1	Inhibition of human MCF7 cell proliferation after 5 days by MTT assay Inhibition of human MCF7 cell proliferation after 5 days by MTT assay	[PMID: 19595598]
MCF7	IC₅₀	8.85 μM Compound: C; Cip	Antitumor activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antitumor activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 34319100]
MG-63	IC₅₀	150 μg/mL Compound: Ciprofloxacin	Inhibition of metabolic activity in MG63 cells assessed as MTT reduction after 48 hrs Inhibition of metabolic activity in MG63 cells assessed as MTT reduction after 48 hrs	[PMID: 17088489]
MG-63	IC₅₀	160 μg/mL Compound: Ciprofloxacin	Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs	[PMID: 17088489]
MG-63	IC₅₀	480 μM Compound: 1	Inhibition of human MG63 cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA Inhibition of human MG63 cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA	[PMID: 19595598]
MRC5	IC₅₀	181 μM Compound: Ciprofloxacin	Cytotoxicity against human MRC5 cells Cytotoxicity against human MRC5 cells	[PMID: 24206766]
MRC5	IC₅₀	53.4 μg/mL Compound: CPF	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31431360]
MT4	CC₅₀	60 μM Compound: Ciprofloxacin	Concentration required to reduce the viability of mock-infected MT-4 cells by 50% Concentration required to reduce the viability of mock-infected MT-4 cells by 50%	[PMID: 10397494]
NCI-H460	IC₅₀	60 μM Compound: 1	Inhibition of human NCI-H460 cell proliferation by sulphorodhamine B assay Inhibition of human NCI-H460 cell proliferation by sulphorodhamine B assay	[PMID: 19595598]
NIH3T3	IC₅₀	>1000 μM Compound: 1	Inhibition of mouse NIH/3T3 cell proliferation by MTT assay Inhibition of mouse NIH/3T3 cell proliferation by MTT assay	[PMID: 19595598]
NIH3T3	IC₅₀	>200 μM Compound: Ciprofloxacin	Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by SRB assay	[PMID: 23711920]
NIH3T3	IC₅₀	>1 mM Compound: 1	Inhibition of mouse NIH/3T3 cell proliferation by MTT assay Inhibition of mouse NIH/3T3 cell proliferation by MTT assay	[PMID: 19595598]
NIH3T3	IC₅₀	305.77 μg/mL Compound: Ciprofloxacin	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 24 hrs by MTT assay Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 24 hrs by MTT assay	[PMID: 28174104]
Osteoblast	IC₅₀	>400 μg/mL Compound: Ciprofloxacin	Inhibition of metabolic activity in primary human osteoblasts assessed as MTT reduction after 48 hrs Inhibition of metabolic activity in primary human osteoblasts assessed as MTT reduction after 48 hrs	[PMID: 17088489]
Osteoblast	IC₅₀	170 μg/mL Compound: Ciprofloxacin	Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs	[PMID: 17088489]
PBMC	IC₅₀	>0.5 mM Compound: CPX, B-H	Cytotoxicity against human PBMC measured after overnight incubation by MTT assay Cytotoxicity against human PBMC measured after overnight incubation by MTT assay	[PMID: 21855181]
PC-3	IC₅₀	101.4 μM Compound: CP	Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31678743]
PC-3	IC₅₀	143 μM Compound: 1	Antitumor activity against human PC3 cells after 5 days by MTT assay Antitumor activity against human PC3 cells after 5 days by MTT assay	[PMID: 19595598]
SH-SY5Y	IC₅₀	>0.5 mM Compound: CPX, B-H	Cytotoxicity against human SH-SY5Y cells measured after overnight incubation by MTT assay Cytotoxicity against human SH-SY5Y cells measured after overnight incubation by MTT assay	[PMID: 21855181]
SK-MEL	IC₅₀	196 μM Compound: 1	Inhibition of human SK-MEL cell proliferation by MTT assay Inhibition of human SK-MEL cell proliferation by MTT assay	[PMID: 19595598]
SK-MEL3	IC₅₀	>128 μM Compound: CFX	Anticancer activity against human SK-MEL3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human SK-MEL3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31881454]
SK-MEL3	IC₅₀	137 μM Compound: Ciprofloxacin	Cytotoxicity against human SK-MEL-3 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human SK-MEL-3 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
SMMC-7721	IC₅₀	>=100 μM Compound: Ciprofloxacin	Antiproliferative activity against human SMMC7721 cells by MTT assay Antiproliferative activity against human SMMC7721 cells by MTT assay	[PMID: 30660827]
SMMC-7721	IC₅₀	137 μM Compound: Ciprofloxacin	Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
Splenocyte	IC₅₀	>40 μM Compound: CIPRO	Cytotoxicity against concanavalin-stimulated BALB/c mouse splenocytes after 72 hrs by resazurin dye reduction method Cytotoxicity against concanavalin-stimulated BALB/c mouse splenocytes after 72 hrs by resazurin dye reduction method	[PMID: 19908867]
SW480	IC₅₀	>128 μM Compound: CFX	Anticancer activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31881454]
SW480	IC₅₀	128 μM Compound: 1	Inhibition of human SW480 cell proliferation by MTT assay Inhibition of human SW480 cell proliferation by MTT assay	[PMID: 19595598]
SW480	IC₅₀	137 μM Compound: Ciprofloxacin	Cytotoxicity against human SW480 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human SW480 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
SW480	IC₅₀	160.4 μM Compound: CP	Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31678743]
SW-620	IC₅₀	200.4 μM Compound: CP	Antiproliferative activity against human SW620 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human SW620 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31678743]
THP-1	IC₅₀	60.5 μM Compound: Ciprofloxacin	Cytotoxicity against human THP1 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human THP1 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24650715]
U-373MG ATCC	IC₅₀	96 μM Compound: 1	Antitumor activity against human U373MG cells after 5 days by MTT assay Antitumor activity against human U373MG cells after 5 days by MTT assay	[PMID: 19595598]
V79	IC₅₀	>1000 μM Compound: 1	Inhibition of chinese hamster V79 cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA Inhibition of chinese hamster V79 cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA	[PMID: 19595598]
V79	IC₅₀	>200 μg/mL Compound: 21 Ciprofloxacin	Clonogenic cytotoxicity against Hamster V-79 cells Clonogenic cytotoxicity against Hamster V-79 cells	[PMID: 8145222]
V79	IC₅₀	>320 μg/mL Compound: 22	Clonogenic cytotoxicity against Chinese hamster V-79 cells Clonogenic cytotoxicity against Chinese hamster V-79 cells	[PMID: 7473575]
V79	IC₅₀	>1 mM Compound: 1	Inhibition of chinese hamster V79 cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA Inhibition of chinese hamster V79 cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA	[PMID: 19595598]
V79	IC₅₀	380 μg/mL Compound: 29a	Mammalian cell cytotoxicity test in chinese hamster V79 cells (clonogenic cytotoxicity) Mammalian cell cytotoxicity test in chinese hamster V79 cells (clonogenic cytotoxicity)	[PMID: 1469702]
V79	IC₅₀	380 μg/mL Compound: 4, Ciprofloxacin	Mammalian cell cytotoxicity test in chinese hamster V79 cells (clonogenic cytotoxicity) Mammalian cell cytotoxicity test in chinese hamster V79 cells (clonogenic cytotoxicity)	[PMID: 1469702]
V79	IC₅₀	380 μg/mL Compound: 40a	Mammalian cell cytotoxicity test in chinese hamster V79 cells (clonogenic cytotoxicity) Mammalian cell cytotoxicity test in chinese hamster V79 cells (clonogenic cytotoxicity)	[PMID: 1469702]
V79-4	IC₅₀	58.55 μg/mL Compound: Ciprofloxacin (CPFX)	Cytotoxicity was determined for the compound in V79-4 cell line Cytotoxicity was determined for the compound in V79-4 cell line	[PMID: 14980680]
Vero	CC₅₀	128 μg/mL Compound: Ciprofloxacin	Cytotoxicity in African green monkey Vero cells Cytotoxicity in African green monkey Vero cells	[PMID: 31358466]
Vero	CC₅₀	128 μg/mL Compound: CPFX	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30025351]
Vero	CC₅₀	512 μg/mL Compound: CPFX	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30690301]
Vero	CC₅₀	600.8 μM Compound: CPFX	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assat Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assat	[PMID: 21146257]
Vero	IC₅₀	>188.5 μM Compound: Ciprofloxacin	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	[PMID: 19131245]
Vero	IC₅₀	192 μM Compound: Ciprofloxacin	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 24206766]
WI-38	IC₅₀	>100 μM Compound: Ciprofloxacin	Antiproliferative activity against human WI38 cells after 24 hrs by BrdU incorporation assay Antiproliferative activity against human WI38 cells after 24 hrs by BrdU incorporation assay	[PMID: 27555286]

In Vitro

Ciprofloxacin (Bay-09867) (5-50 μg/mL; 0-24 h; tendon cells) inhibits cell proliferation and causes cell cycle arrest at the G2/M phase^[1].
Ciprofloxacin (Bay-09867) shows potent activity against Y. pestis and B. anthracis with MIC₉₀ of 0.03 μg/mL and 0.12 μg/mL, respectively^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis^[1]

Cell Line:	Tendon cells
Concentration:	5, 10, 20 and 50 μg/mL
Incubation Time:	24 hours
Result:	Decreased the cellularity of tendon cells.

Apoptosis Analysis^[1]

Cell Line:	Tendon cells
Concentration:	50 μg/mL
Incubation Time:	24 hours
Result:	Arrested cell cycle at the G2/M phase and inhibited cell division in tendon cells.

Western Blot Analysis^[1]

Cell Line:	Tendon cells
Concentration:	50 μg/mL
Incubation Time:	0, 6, 12, 17 and 24 hours
Result:	Down-regulated the expression of CDK-1 and cyclin B protein and mRNA. Up-regulated the expression of PLK-1 protein.

In Vivo

Ciprofloxacin (Bay-09867) (30 mg/kg; i.p.; for 24 hours; BALB/c mice) has protection against Y. pestis in murine model of pneumonic plague^[3].
Ciprofloxacin (Bay-09867) (100 mg/kg; i.g.; daily, for 4 weeks; C57BL/6J mice) accelerates aortic root enlargement and increases the incidence of aortic dissection and rupture by decreases LOX level and increases MMP levels and activity in the aortic wall^[4].
Ciprofloxacin (Bay-09867) (100 mg/kg; i.g.; daily, for 4 weeks; C57BL/6J mice) induces DNA damage and release of DNA to the cytosol, mitochondrial dysfunction, and activation of cytosolic DNA sensor signaling. Ciprofloxacin lactate increases apoptosis and necroptosis in the aortic wall^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/c mice^[3]
Dosage:	30 mg/kg
Administration:	Intraperitoneal injection; for 24 hours
Result:	Reduced the lung bacterial load in murine model of pneumonic plague.

Animal Model:	C57BL/6J mice^[4]
Dosage:	100 mg/kg
Administration:	Oral gavage; daily, for 4 weeks
Result:	Had aortic destruction that was accompanied by decreased LOX expression and increased MMP expression and activity.

Animal Model:	C57BL/6J mice^[4]
Dosage:	100 mg/kg
Administration:	Oral gavage; daily, for 4 weeks
Result:	Caused mitochondrial DNA and nuclear DNA damage, leading to mitochondrial dysfunction and ROS production. Increased apoptosis and necroptosis in the aortic wall.

Masse moléculaire

331.34

Formule

C₁₇H₁₈FN₃O₃

CAS No.

85721-33-1

Appearance

Solid

Color

White to off-white

SMILES

O=C(C1=CN(C2CC2)C3=C(C=C(F)C(N4CCNCC4)=C3)C1=O)O

Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvant et solubilité

In Vitro:

0.1 M HCl : 16.67 mg/mL (50.31 mM; ultrasonic and warming and adjust pH to 2 with HCl and heat to 60°C)

H₂O : 5.65 mg/mL (17.05 mM; ultrasonic and adjust pH to 2 with 1 M HCl)

DMSO : 4.86 mg/mL (14.67 mM; ultrasonic and warming and adjust pH to 5 with 1 M HCl and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.0180 mL	15.0902 mL	30.1805 mL
5 mM	0.6036 mL	3.0180 mL	6.0361 mL
10 mM	0.3018 mL	1.5090 mL	3.0180 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Calculateur de molarité
Calculateur de dilution

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Pureté et documentation

Purity: 99.81%

Fiche technique (280 KB) SDS (393 KB)

COA (247 KB) RP-HPLC (255 KB) MS (68 KB)

Instruction de manipulation (2659 KB)

Références

[1]. Tsai WC, et, al. Ciprofloxacin-mediated cell proliferation inhibition and G2/M cell cycle arrest in rat tendon cells. Arthritis Rheum. 2008 Jun;58(6):1657-63. [Content Brief]

[2]. Steenbergen J, et, al. In Vitro and In Vivo Activity of Omadacycline against Two Biothreat Pathogens, Bacillus anthracis and Yersinia pestis. Antimicrob Agents Chemother. 2017 Apr 24;61(5):e02434-16. [Content Brief]

[3]. Hamblin KA, et, al. Inhaled Liposomal Ciprofloxacin Protects against a Lethal Infection in a Murine Model of Pneumonic Plague. Front Microbiol. 2017 Feb 6;8:91.

[4]. LeMaire SA, et, al. Effect of Ciprofloxacin on Susceptibility to Aortic Dissection and Rupture in Mice. JAMA Surg. 2018 Sep 1;153(9):e181804. [Content Brief]

Você também pode estar interessado nos seguintes produtos:

Referência

Descrição

Cond.

Price Bef. VAT

MD-14-0034P

Human Ferritin

1mg

227-10152

Human Liver Ferritin

1mg

228-10442-2

Ferritin, Human Recombinant, Heavy Chain

25ug

Ciprofloxacin [85721-33-1]

Referência HY-B0356-5g

Contactar o distribuidor local :

Marca : MedChemExpress

Contactar o distribuidor local :

Ciprofloxacin Related Antibodies

Calculateur de molarité

Calculateur de dilution

Você também pode estar interessado nos seguintes produtos: